Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Feladilimab by GSK for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
Feladilimab by GSK for Oropharyngeal Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
Feladilimab by GSK for Laryngeal Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
Feladilimab by GSK for Hypopharyngeal Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...
GSK-1070806 by GSK for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
GSK-1070806 is under clinical development by GSK and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData,...
Bepirovirsen sodium by GSK for Hepatitis B: Likelihood of Approval
Bepirovirsen sodium is under clinical development by GSK and currently in Phase III for Hepatitis B. According to GlobalData, Phase...
Camlipixant by GSK for Chronic Cough: Likelihood of Approval
Camlipixant is under clinical development by GSK and currently in Phase III for Chronic Cough. According to GlobalData, Phase III...
Feladilimab by GSK for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...
Belantamab mafodotin by GSK for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Belantamab mafodotin by GSK for Amyloidosis: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Amyloidosis. According to GlobalData, Phase II...
Belantamab mafodotin by GSK for Relapsed Multiple Myeloma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Pre-Registration for Relapsed Multiple Myeloma. According to GlobalData, Pre-Registration...
Belantamab mafodotin by GSK for Refractory Multiple Myeloma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Pre-Registration for Refractory Multiple Myeloma. According to GlobalData, Pre-Registration...
Feladilimab by GSK for Non-Small Cell Lung Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Dostarlimab by GSK for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Camlipixant by GSK for Chronic Cough: Likelihood of Approval
Camlipixant is under clinical development by GSK and currently in Phase III for Chronic Cough. According to GlobalData, Phase III...
Feladilimab by GSK for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...
GSK-3888550A by GSK for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
GSK-3888550A is under clinical development by GSK and currently in Phase III for Respiratory Syncytial Virus (RSV) Infections. According to...
Risk adjusted net present value: What is the current valuation of GSK's Linerixibat?
Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of GSK's Cobolimab?
Cobolimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Non-Small Cell Lung Carcinoma;Squamous Non-Small...
Risk adjusted net present value: What is the current valuation of GSK's GSK-4178116A?
GSK-4178116A is a live attenuated vaccine commercialized by GSK, with a leading Phase II program in Chicken Pox. According to...